Atorvia Health Technologies
Atorvia is an early-stage biotech company focused on ending organ failure, starting with kidney failure. They research the biological mechanisms causing organ dysfunction, particularly how kidney cells become programmed to die, and use machine learning to engineer novel peptide therapeutics targeting these cells to prevent death. Their lead programs aim to treat Acute Kidney Injury (AKI), a condition affecting 1 in 4 hospitalized patients with no current treatment options. Atorvia also develops novel protein biomarkers for early detection and diagnosis of kidney failure. The company combines cutting-edge science with commercial strategies, emphasizing patient, physician, and payer needs. Headquartered in Ottawa with lab space in Toronto, Atorvia is a women- and BIPOC-founded company with a diverse and inclusive culture.
Atorvia Health Technologies
Atorvia is an early-stage biotech company focused on ending organ failure, starting with kidney failure. They research the biological mechanisms causing organ dysfunction, particularly how kidney cells become programmed to die, and use machine learning to engineer novel peptide therapeutics targeting these cells to prevent death. Their lead programs aim to treat Acute Kidney Injury (AKI), a condition affecting 1 in 4 hospitalized patients with no current treatment options. Atorvia also develops novel protein biomarkers for early detection and diagnosis of kidney failure. The company combines cutting-edge science with commercial strategies, emphasizing patient, physician, and payer needs. Headquartered in Ottawa with lab space in Toronto, Atorvia is a women- and BIPOC-founded company with a diverse and inclusive culture.